Cargando…
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
In cancer chemotherapy neutropenia is a common dose-limiting toxicity. An ability to predict the neutropenic effects of cytotoxic agents based on proposed trial designs and models conditioned on previous studies would be valuable. The aim of this study was to evaluate the ability of a semi-mechanist...
Autores principales: | Soto, Elena, Keizer, Ron J., Trocóniz, Iñaki F., Huitema, Alwin D. R., Beijnen, Jos H., Schellens, Jan H. M., Wanders, Jantien, Cendrós, Josep María, Obach, Rosendo, Peraire, Concepción, Friberg, Lena E., Karlsson, Mats O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160557/ https://www.ncbi.nlm.nih.gov/pubmed/20449627 http://dx.doi.org/10.1007/s10637-010-9437-z |
Ejemplares similares
-
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
por: Zandvliet, Anthe S., et al.
Publicado: (2009) -
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011) -
Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016) -
Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019) -
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
por: van der Noll, R., et al.
Publicado: (2015)